HealthCare Ventures

Leap Therapeutics, Macrocure to merge

Wednesday, September 7, 2016

Leap Therapeutics, a clinical stage immuno-oncology company, and Macrocure have announced the signing of a definitive merger agreement. Under the terms of the agreement, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company. In connection with the transaction, Leap will apply to have the shares of the combined entity listed for trading on NASDAQ upon completion of the merger.

[Read More]

MIMETAS appoints Todd Chappell general manager, U.S. Affairs

Tuesday, January 7, 2014

BioHealth Innovation (BHI) and MIMETAS, a developer of organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models, have announced Todd Chappell, MBA, an entrepreneur-in-residence for BHI, has been named general manager, U.S. Affairs for MIMETAS. A Netherlands-based company, MIMETAS is establishing its offices within BHI’s headquarters in Rockville, Md. MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.

[Read More]

Tensha completes $15 million Seires A financing round

Monday, September 12, 2011

Tensha Therapeutics has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes. The company’s lead program, presently in preclinical development, is a first-in-class small molecule aimed at the treatment of BRD4-NUT midline carcinoma (a rare, invariably fatal cancer), acute myeloid leukemias, multiple myeloma, and other malignancies. HealthCare Ventures is the sole investor in the financing.

[Read More]